Welcome to the Future of Longevity Medicine

The future of medicine is increasingly focused on longevity, with world leaders and scientific institutions exploring radical life extension. Russian President Vladimir Putin and Chinese President Xi Jinping reportedly discussed visionary ideas about extending human life, with Putin suggesting that continuous organ transplantation could lead to immortality and Xi Jinping envisioning lifespans of up to 150 years by the end of this century. Russia has already committed to a substantial $26 billion program for life extension, encompassing gene therapy and 3D organ printing, which began in 2024.

Significant scientific progress is being made. In April, Russia's Deputy Minister of Science, Denis Sekirinski, announced the development of the world's first gene therapy targeting the RAGE receptor, a key factor in cellular aging. Furthermore, in January 2026, the U.S. FDA approved the first-ever human clinical trial based on partial epigenetic reprogramming. This trial will use three Yamanaka factors (OSK) to attempt to rejuvenate damaged retinal cells in patients suffering from glaucoma and "optic nerve atrophy."

“

With continuous human organ transplantation, the body can be eternal.

These developments challenge the long-held belief that aging is merely a matter of time and fate. Gerontology research now reveals aging as a complex interplay of biological mechanisms that can be influenced. Factors such as chronic inflammation, mitochondrial decline, the accumulation of "zombie cells," and telomere shortening are not just scientific terms but processes that dictate the length and quality of human life. Crucially, these processes can be impacted by daily decisions, including diet, sleep quality, and stress management.

The pursuit of longevity is also a significant financial consideration. Chronic diseases are projected to cost the global economy $47 trillion by 2030, impacting healthcare systems, employers through absenteeism, and national GDP. The distinction between lifespan (how long one lives) and healthspan (how healthily one lives) is critical. Approaches range from the expensive, such as young blood transfusions (once commercialized by the U.S. startup Ambrosia), to regular oral intake of substances like rapamycin, senolytics, metformin, and growth hormones, promoted by figures like geneticist David Sinclair and physician Peter Attia. Bryan Johnson, founder of Braintree and Venmo, has notably converted his substantial tech fortune into an obsession with anti-aging.

“

We should live up to 150 years by the end of this century.